Biofrontera Q2 revenue $7.8M (+34% YoY); net loss narrows to $0.3M from $9.8M

Biofrontera Inc.

2024-Q2 EPS reported -$2.45 revenue$15,750,000

Q2 2024 total revenues $7.8M, up 34% from $5.8M in Q2 2023; catch-up from lower 1Q sales due to Change Healthcare cyber event.
Net loss improved to $257K from $9.8M; adjusted EBITDA -$4.7M vs -$7.9M in prior year.
Cash and equivalents $4.4M at June 30, 2024, up from $1.3M at Dec 31, 2023; raised $8.0M from May 2024 warrant exercises.
Launched FDA-approved RhodoLED XL lamp in June; shipped first three machines within one week of launch.
Took control of all US clinical trials for Ameluz on June 1, 2024, under amended license agreement to reduce costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.